Mustang Bio, Inc. (MBIO) is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Mustang Bio aims to improve the lives of individuals who have limited or no treatment options, transforming advanced research into widely accessible therapeutic solutions.
Founded in 2015, Mustang Bio is headquartered in Worcester, Massachusetts. The company is part of the Fortress Biotech family, which consists of a diverse group of biotech companies developing novel solutions in health and medicine. This gives Mustang Bio access to a network of shared resources and research, promoting a dynamic and vibrant scientific environment.
Mustang Bio's robust pipeline of innovative therapies is developed in collaboration with leading research institutions, including City of Hope National Medical Center and the Fred Hutchinson Cancer Research Center. Through these partnerships, Mustang Bio seeks to advance its chimeric antigen receptor (CAR) T-cell therapy portfolio, which harnesses the body's immune system to fight cancer, alongside other groundbreaking therapies like lentiviral gene therapies for rare genetic disorders.
One noteworthy therapy in development is MB-107, a lentiviral gene therapy for X-linked severe combined immunodeficiency ('bubble boy disease') that has demonstrated promising clinical results. Their CAR-T therapies, such as MB-102 (for acute myeloid leukemia), are also making a mark in the oncology field.
Transparency and communication are key to Mustang Bio's operations. They regularly share updates about their research's progress, enabling stakeholders to stay informed about ongoing developments.
Recognizing the heavy investment that groundbreaking therapies necessitate, Mustang Bio is committed to partnering with reputable academic institutions, esteemed clinicians, and global biotech companies. These partnerships aim to maximize the potential for their research breakthroughs to become viable therapies in the healthcare market.
The company strives for quality in all areas, maintaining rigorous standards in its scientific practices. This commitment to excellence extends to their business ethics, with corporate governance mechanisms in place to ensure responsible and accountable operations.
In short, Mustang Bio, Inc. is a forward-thinking company dedicated to making a meaningful difference in the field of biomedicine. Their efforts in developing and delivering pioneering cell and gene therapies embody a blend of cutting-edge science, operational excellence, and a deep-seated passion for improving patient outcomes.